Table 1 Demographic and clinical features of subjects.

From: Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome

Parameters AMAN (n = 52) AIDP (n = 20) Unclassified (n = 14)
Age at disease onset (years) 46.23 ± 15.74 (17–75) 41.95 ± 20.30 (17–76) 43.21 ± 15.73 (24–75)
Gender (F/M) 23/29 7/13 8/6
Symptoms preceding infection 27 8 7
Diarrhea 14 3 3
Upper respiratory tract infection 13 5 4
GBS disability score at 2 weeks after entry 3.67 ± 0.86 2.55 ± 1.23** 1.79 ± 0.98**
Erasmus GBS outcome score 4.52 ± 1.00 3.15 ± 1.61** 2.14 ± 1.09**
Anti-ganglioside antibody (%)
Anti-GM1-positive 36.96 16.67 7.14
Anti-GQ1b-positive 8.70 5.00 42.86
WBC in CSF (106/L) 2 (0–10) 2 (0–10) 2 (0–6)
Protein in CSF (g/L) 1.16 ± 0.66 0.72 ± 0.35* 0.72 ± 0.37*
  1. Data are expressed as mean ± SD, Mann–Whitney U tests were used for statistical analysis. *Statistically significant in comparison with AMAN, *P < 0.05, **P < 0.001. AMAN, acute motor axonal neuropathy; AIDP, acute inflammatory demyelinating polyneuropathy; CSF, cerebrospinal fluid; GBS, Guillain-Barré syndrome.